Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
US Army
Colorcon
Cipla
Moodys
UBS
Cantor Fitzgerald
Merck
Fuji
QuintilesIMS

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,888,027

« Back to Dashboard

Which drugs does patent 6,888,027 protect, and when does it expire?

Patent 6,888,027 protects BELEODAQ and is included in one NDA.

This patent has sixteen patent family members in eleven countries.
Summary for Patent: 6,888,027
Title: Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Abstract:This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: --S(.dbd.O).sub.2 NR.sup.1 -- and --NR.sup.1 S(.dbd.O).sub.2 --; R1 is a sulfonamido substituent; and, Q.sup.2 is an acid leader group; with the proviso that if J is --S(.dbd.O).sub.2 NR.sup.1 --, then Q.sup.1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis. ##STR1##
Inventor(s): Watkins; Clare J (Abingdon, GB), Romero-Martin; Maria Rosario (Didcot, GB), Moore; Kathryn G (Abingdon, GB), Ritchie; James (Abingdon, GB), Finn; Paul W (Abingdon, GB), Kalvinsh; Ivars (Riga, LV), Loza; Einars (Riga, LV), Dikovska; Klara (Riga, LV), Gailite; Vija (Riga, LV), Vorona; Maxim (Riga, LV), Piskunova; Irina (Riga, LV), Starchenkov; Igor (Riga, LV), Andrianov; Victor (Riga, LV), Harris; C. John (Sittingbourne, GB), Duffy; James E. S. (Sittingbourne, GB)
Assignee: Topotarget UK Limited (Abingdon, GB)
Application Number:10/381,790
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,888,027

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Spectrum Pharms BELEODAQ belinostat POWDER;IV (INFUSION) 206256-001 Jul 3, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL). ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,888,027

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0023986Sep 29, 2000
PCT Information
PCT FiledSeptember 27, 2001PCT Application Number:PCT/GB01/04326
PCT Publication Date:April 18, 2002PCT Publication Number: WO02/30879

Non-Orange Book US Patents Family Members for Patent 6,888,027

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,183,298 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
7,407,988 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
7,557,140 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,888,027

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2001290131 ➤ Sign Up
Australia 9013101 ➤ Sign Up
Canada 2423744 ➤ Sign Up
Canada 2765409 ➤ Sign Up
Cyprus 1114818 ➤ Sign Up
Denmark 1328510 ➤ Sign Up
European Patent Office 1328510 ➤ Sign Up
European Patent Office 2292593 ➤ Sign Up
Spain 2445578 ➤ Sign Up
United Kingdom 0023986 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
US Army
Chinese Patent Office
Daiichi Sankyo
UBS
US Department of Justice
Express Scripts
QuintilesIMS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot